Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Jennifer A. Kanakry et al.|Blood|2015Cited by 299
The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseasesJennifer A. Kanakry, Alexandra Valsamakis, Aparna Hegde et al.|Blood|2016Cited by 229
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R. McCurdy, Leo Luznik, Yvette L. Kasamon et al.|Haematologica|2016Cited by 187
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysisScott Goldsmith, Marcie Riches, Jennifer A. Kanakry et al.|Blood|2021Cited by 177
Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease ProphylaxisJennifer A. Kanakry, Richard F. Ambinder, Yvette L. Kasamon et al.|Biology of Blood and Marrow Transplantation|2013Cited by 114